TCR-T Cells in the Treatment of Advanced Pancreatic Cancer (GB3010-02)

Inclusion Criteria: To be eligible for the study, patients must meet all of the following criteria: Male or female, aged 18-75 years; Patients with advanced pancreatic cancer diagnosed by histology or cytology, patients who failed to respond to standard treatment, relapsed or voluntarily gave up; Patients must have tumor tissue that expresses specific tumor antigens, such as mutations in RAS and/or TP53; Patients must undergo HLA matching testing and meet the requirements of HLA matching. At least one measurable or evaluable lesion ≥15 mm according to RECIST1.1 criteria; Patients with ECOG < 2 and life expectancy ≥3 months; a) Liver function: ALT/AST < 3 times the upper limit of normal value (ULN) and bilirubin ≤34.2μmol/L; b) renal function: creatinine < 220μmol/L; c) terminal oxygen saturation ≥95% in room air; d) Cardiac function: left ventricular ejection fraction (LVEF) ≥60%; e) Blood routine: absolute neutrophil count ≥ 1×109/L; Platelet count ≥70×109/L; Absolute lymphocyte count ≥100 cells /μL; The patients met the requirements of apheresis without any contraindications. Women of childbearing age who have a negative urine pregnancy test at screening and before starting dosing and who have agreed to use highly effective contraception for at least 100 days after infusion; Female participants must agree not to donate eggs (oocytes, oocytes) for assisted reproductive purposes during the study and for 90 days after receiving the last study drug; Male subjects with a fertile partner must consent to use an effective barrier method of contraception for at least 100 days after infusion; Must agree not to donate sperm for at least one year; Sign an informed consent form. Exclusion Criteria: Patients who met any of the following criteria were not eligible for inclusion in the study: Persons with severe mental disorders; A positive virological test for any of the following: HIV; HCV; HBsAg; HBcAb was positive, and HBV DNA copy number and TPPA were positive. Patients with severe allergic history or allergic constitution; Severe underlying medical conditions such as evidence of other serious active viral, bacterial or uncontrolled systemic fungal infection; Active autoimmune disease or a history of autoimmune disease within 3 years; A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic immunosuppressive/systemic disease modulating drugs within the past 2 years; Combined with organ dysfunction, such as renal insufficiency; Had been enrolled in another clinical trial within 4 weeks before enrollment in the trial; Those who were unable to comply with the study protocol and follow-up plan due to physiological, family, social, geographical and other factors; Patients with contraindications to cyclophosphamide or fludarabine chemotherapy; Subjects who required additional immunosuppressive drug therapy within 72 hours before TCR-T infusion, except for the treatment of adverse events during the trial; Pregnant, lactating women, or men who plan to have children while participating in the study or within 100 days of receiving study treatment; Any other condition considered by the investigator to be ineligible for enrollment.